Concert Pharmaceuticals Expands Management Team
September 06 2016 - 7:00AM
Business Wire
Appointment of Two Executives to Support
Advancement of Product Pipeline: Christine Boisclair Named Vice
President, Regulatory Affairs, and Scott Weintraub Named Vice
President, Commercial and Product Strategy
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the
expansion of its senior management team with the appointment of
executives in regulatory affairs and commercial strategy to serve
in leadership roles as the Company advances its clinical pipeline.
Christine Boisclair has been appointed as Vice President,
Regulatory Affairs, with primary responsibility for planning and
coordinating Concert’s regulatory submissions to the U.S. Food and
Drug Administration (FDA) and other regulatory authorities. She
replaces Mark Roessel, who recently retired following a long and
successful career in the pharmaceutical industry. Scott Weintraub
has joined Concert in the newly created position of Vice President,
Commercial and Product Strategy, with responsibilities including
overseeing the Company’s commercial strategy and market assessments
for Concert’s drug candidates and pipeline.
“We are delighted that Christine and Scott will contribute their
expertise and talents to Concert’s success in our next stage of
growth as we continue to advance our product candidates toward
approval,” said Roger Tung, Ph.D., President and CEO of Concert
Pharmaceuticals, Inc. “The addition of these outstanding leaders to
our management team reflects the substantial progress we have made
to date with our product candidates for the treatment of cystic
fibrosis and alopecia areata.”
Christine Boisclair, Vice President, Regulatory
AffairsMs. Boisclair joins Concert with more than 30 years of
regulatory affairs experience in the biopharmaceutical industry
across multiple therapeutic areas. Prior to joining Concert, Ms.
Boisclair was Vice President, Regulatory Affairs, at Forum
Pharmaceuticals. Before joining Forum Pharmaceuticals, she held
management roles at several companies including Insmed, Agennix,
OSI Pharmaceuticals, Genzyme Corporation, Immulogic Pharmaceuticals
and Parexel International. Ms. Boisclair also worked in regulatory
at Searle Pharmaceuticals and Glaxo in the U.K. She received a
Bachelor of Science Honors Degree in Biochemistry from the
University of York in the U.K.
Scott Weintraub, Vice President, Commercial and Product
StrategyMr. Weintraub joins Concert with more than 17 years of
commercial experience in the biopharmaceutical industry, including
strategic product assessment, brand positioning, commercial life
cycle management, and sales and marketing. Prior to joining
Concert, he was Vice President of Product Strategy and Marketing at
Forum Pharmaceuticals. He also served as Senior Director of
Marketing at Sunovion Pharmaceuticals and held sales and marketing
positions at AstraZeneca. He holds a B.S. in Finance and Marketing
from Florida State University and an M.B.A. in Health
Administration and Policy from University of Miami.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical
company focused on applying its DCE Platform® (deuterated chemical
entity platform) to create novel medicines designed to address
unmet patient needs. The Company’s approach starts with approved
drugs in which deuterium substitution has the potential to enhance
clinical safety, tolerability or efficacy. Concert has a broad
pipeline of innovative medicines targeting pulmonary diseases,
including cystic fibrosis, central nervous systems (CNS) disorders,
as well as autoimmune and inflammatory diseases. For more
information please visit www.concertpharma.com.
Concert Pharmaceuticals Inc., the CoNCERT
Pharmaceuticals Inc. logo and DCE Platform are registered
trademarks of Concert Pharmaceuticals, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160906005210/en/
InvestorsConcert Pharmaceuticals, Inc.Justine E. Koenigsberg,
781-674-5284ir@concertpharma.comorMediaThe Yates NetworkKathryn
Morris, 845-635-9828
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024